These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 9083881)

  • 1. Delivery of noncommitted shocks for nonsustained ventricular arrhythmias by a new implantable cardioverter defibrillator with abortive shock capability.
    Blanck Z; Biehl M; Sra J; Dhala A; Akhtar M
    J Cardiovasc Electrophysiol; 1997 Mar; 8(3):317-22. PubMed ID: 9083881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of long detection interval implantable cardioverter-defibrillator settings in secondary prevention population: data from the Avoid Delivering Therapies for Nonsustained Arrhythmias in ICD Patients III (ADVANCE III) trial.
    Kloppe A; Proclemer A; Arenal A; Lunati M; Martìnez Ferrer JB; Hersi A; Gulaj M; Wijffels MC; Santi E; Manotta L; Mangoni L; Gasparini M
    Circulation; 2014 Jul; 130(4):308-14. PubMed ID: 24838360
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Importance of abortive shock capability with electrogram storage in cardioverter-defibrillator devices.
    Hurwitz JL; Hook BG; Flores BT; Marchlinski FE
    J Am Coll Cardiol; 1993 Mar; 21(4):895-900. PubMed ID: 8450157
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcomes of defibrillator therapy in catecholaminergic polymorphic ventricular tachycardia.
    Roses-Noguer F; Jarman JW; Clague JR; Till J
    Heart Rhythm; 2014 Jan; 11(1):58-66. PubMed ID: 24120999
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lessons learned from data logging in a multicenter clinical trial using a late-generation implantable cardioverter-defibrillator. The Guardian ATP 4210 Multicenter Investigators Group.
    Wood MA; Stambler BS; Damiano RJ; Greenway P; Ellenbogen KA
    J Am Coll Cardiol; 1994 Dec; 24(7):1692-9. PubMed ID: 7963117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inappropriate shock delivery by implantable defibrillators with dual chamber pacing during nonsustained ventricular tachycardia in patients with heart block.
    Sra J; Akhtar M
    Pacing Clin Electrophysiol; 2000 Jun; 23(6):1054-6. PubMed ID: 10879396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long Detection Programming in Single-Chamber Defibrillators Reduces Unnecessary Therapies and Mortality: The ADVANCE III Trial.
    Gasparini M; Lunati MG; Proclemer A; Arenal A; Kloppe A; Martínez Ferrer JB; Hersi AS; Gulaj M; Wijffels MCE; Santi E; Manotta L; Varma N
    JACC Clin Electrophysiol; 2017 Nov; 3(11):1275-1282. PubMed ID: 29759624
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of third-generation implantable cardioverter defibrillators to abort shock therapy for nonsustained ventricular tachycardia due to shortcomings of the VF confirmation algorithm.
    Grimm W; Menz V; Hoffmann J; Maisch B
    Pacing Clin Electrophysiol; 1998 Apr; 21(4 Pt 1):722-7. PubMed ID: 9584303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Etiology and Programming Effects on Shock Efficacy in ICD Recipients.
    Bertomeu-González V; Moreno-Arribas J; Castillo-Castillo J; Martínez-Ferrer J; Viñolas X; Rodríguez A; Díaz-Infante E; Fernández-Lozano I; Alzueta J; Fontenla A
    Pacing Clin Electrophysiol; 2016 Jan; 39(1):73-80. PubMed ID: 26450114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Driving and implantable cardioverter-defibrillator shocks for ventricular arrhythmias: results from the TOVA study.
    Albert CM; Rosenthal L; Calkins H; Steinberg JS; Ruskin JN; Wang P; Muller JE; Mittleman MA;
    J Am Coll Cardiol; 2007 Dec; 50(23):2233-40. PubMed ID: 18061071
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Survival after shock therapy in implantable cardioverter-defibrillator and cardiac resynchronization therapy-defibrillator recipients according to rhythm shocked. The ALTITUDE survival by rhythm study.
    Powell BD; Saxon LA; Boehmer JP; Day JD; Gilliam FR; Heidenreich PA; Jones PW; Rousseau MJ; Hayes DL
    J Am Coll Cardiol; 2013 Oct; 62(18):1674-1679. PubMed ID: 23810882
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Strategic programming of detection and therapy parameters in implantable cardioverter-defibrillators reduces shocks in primary prevention patients: results from the PREPARE (Primary Prevention Parameters Evaluation) study.
    Wilkoff BL; Williamson BD; Stern RS; Moore SL; Lu F; Lee SW; Birgersdotter-Green UM; Wathen MS; Van Gelder IC; Heubner BM; Brown ML; Holloman KK;
    J Am Coll Cardiol; 2008 Aug; 52(7):541-50. PubMed ID: 18687248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mortality reduction in relation to implantable cardioverter defibrillator programming in the Multicenter Automatic Defibrillator Implantation Trial-Reduce Inappropriate Therapy (MADIT-RIT).
    Ruwald AC; Schuger C; Moss AJ; Kutyifa V; Olshansky B; Greenberg H; Cannom DS; Estes NA; Ruwald MH; Huang DT; Klein H; McNitt S; Beck CA; Goldstein R; Brown MW; Kautzner J; Shoda M; Wilber D; Zareba W; Daubert JP
    Circ Arrhythm Electrophysiol; 2014 Oct; 7(5):785-92. PubMed ID: 25136077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced risk for inappropriate implantable cardioverter-defibrillator shocks with dual-chamber therapy compared with single-chamber therapy: results of the randomized OPTION study.
    Kolb C; Sturmer M; Sick P; Reif S; Davy JM; Molon G; Schwab JO; Mantovani G; Dan D; Lennerz C; Borri-Brunetto A; Babuty D
    JACC Heart Fail; 2014 Dec; 2(6):611-9. PubMed ID: 25282033
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Feedback to providers improves evidence-based implantable cardioverter-defibrillator programming and reduces shocks.
    Silver MT; Sterns LD; Piccini JP; Joung B; Ching CK; Pickett RA; Rabinovich R; Liu S; Peterson BJ; Lexcen DR;
    Heart Rhythm; 2015 Mar; 12(3):545-553. PubMed ID: 25460168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical performance of a specific algorithm to reconfirm self-terminating ventricular arrhythmias in current implantable cardioverter-defibrillators.
    Raedle-Hurst TM; Wiecha J; Schwab JO; Schmitt H; Hinrichs M; Tillmanns H; Waldecker B
    Am J Cardiol; 2001 Oct; 88(7):744-9. PubMed ID: 11589840
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness of subcutaneous implantable cardioverter-defibrillators and determinants of inappropriate shock delivery.
    Mesquita J; Cavaco D; Ferreira A; Lopes N; Santos PG; Carvalho MS; Haas A; Costa F; Carmo P; Morgado F; Adragão P; Mendes M
    Int J Cardiol; 2017 Apr; 232():176-180. PubMed ID: 28082086
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of a discrimination algorithm to reduce inappropriate shocks with a subcutaneous implantable cardioverter-defibrillator.
    Gold MR; Weiss R; Theuns DA; Smith W; Leon A; Knight BP; Carter N; Husby M; Burke MC
    Heart Rhythm; 2014 Aug; 11(8):1352-8. PubMed ID: 24732366
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and efficacy of strategic implantable cardioverter-defibrillator programming to reduce the shock delivery burden in a primary prevention patient population.
    Buber J; Luria D; Gurevitz O; Bar-Lev D; Eldar M; Glikson M
    Europace; 2014 Feb; 16(2):227-34. PubMed ID: 24108231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcome of patients with malignant ventricular tachyarrhythmias and a multiprogrammable implantable cardioverter-defibrillator implanted with or without thoracotomy: an international multicenter study. PCD Investigator Group.
    J Am Coll Cardiol; 1994 Jun; 23(7):1521-30. PubMed ID: 8195508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.